News

"We share Discovery's passion for science and believe that combining our expertise in cell-based assays and drug screening with Discovery's broad multi-omics capabilities will enable us to provide a....

Seattle-based primary cell biology CRO ReachBio and Swiss biotech abc biopply announced today a partnership to jointly co-market their preclinical test models. The two companies plan to support their....

The ReachBio team is delighted to be returning to the Annual Meeting for The American Association of Immunologists next month in Portland, Oregon. Our CSO, Dr. Emer Clarke, will be presenting a....

March 2-5 2020 | London, UK

ReachBio is please to be participating in the 10th annual  World ADC San Diego conference as a select exhibitor. ReachBio is the only CRO providing toxicity assays that will be exhibiting at this....

An article referencing ReachBio's newdrug screening platform to discover therapeutic compounds that trigger the production of fetal hemoglobin (HbF) to treat sickle cell disease (SCD) and other....

SEATTLE, August 13, 2019 -- ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering a drug screening platform to assess....

SEATTLE, July 9, 2019 -- ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering off-target toxicity and linker....

Once again, ReachBio is excited to announce our continued sponsorship for the annual Applied Pharmaceutical Toxicology (APT) Conference  in South San Francisco, California. This year's event will....

ReachBio will be exhibiting at this year’s ToxExpo at the Society of Toxicology (SOT) 58^thAnnual Meeting in Baltimore, Maryland. Stop by our booth, #4121, to learn about our latest assays to help....

ReachBio is excited to announce that we are slated to sponsor this year's Applied Pharmaceutical Toxicology (APT) Conference  in Boston, Massachusettsat the Merck Research Laboratories, May 15th....

ReachBio will be returning to and exhibiting at this year’s ToxExpo at the Society of Toxicology (SOT) 57^th Annual Meeting in San Antonio, Texas. Our booth, #1631, will display a range of....

SEATTLE, May 9, 2017 -- ReachBio Research Labs (trade name under ReachBio LLC), a CRO specializing in primary cell assay services and products, is now offering sourced, enriched and tested primary....

We're excited to announce we'll be exhibiting at this year's Applied Pharmaceutical Toxicology (APT) Conference  in San Francisco, California at Genentech in building 35, May 15th - 17th.

We are pleased to announce that ReachBio will be exhibiting at this year’s ToxExpo at the Society of Toxicology (SOT) 56^th Annual Meeting in Baltimore, Maryland. Our booth, number 1616, will display....

SEATTLE, Jan. 31, 2017 /PRNewswire/ -- ReachBio Research Labs (trade name under Reachbio LLC®) has announced the launch of their new drug development platform, cellPrism®. The platform is designed to....

ReachBio Research Labs now makes it easy for you to purchase Human Peripheral Blood Mononuclear Cells (PBMCs) online! The blood that is used to make our primary cell products is obtained from healthy....

Join us June 15th through the 17th, 2016 at the 15th Annual World Preclinical Congress in Boston, MA! Stop by booth #207, and meet our CSO, Dr. Emer Clarke, and Lead Scientist, Gary dos Santos. 

The Society of Toxicology 55th Annual Meeting and ToxExpo is next week! ReachBio will be exhibiting at the ToxExpo from March 14th through the 16th. We welcome all to stop by our booth #1300 to talk....

It has been a good year for growth at ReachBio Research Labs! We have really appreciated working with our existing clients who have come back, time after time with new contract services. We have....

Thank you to everyone who took the time to visit with us at the American College of Toxicology (ACT) 2015 36th Annual Meeting, this week. We had a great time, and look forward to seeing everyone,....

The colony forming unit-megakaryocyte assay, better known as the CFU-Mk assay is a robust and predictive in vitro assay for evaluating the toxicity of test compounds on megakaryocytic progenitors.....

If your drug development program has a particular lineage-specific hemotoxicity issue such as neutropenia (myeloid lineage toxicity), acute anemia (erythroid lineage toxicity) or thrombocytopenia....

Interested in in vitro assays to assess the risk of cytokine storms? Or in vitro evaluation of compound effects on leukemic progenitors vs normal progenitors? So are we!

SOT 2014 Posters Available for Download!

ReachBio Research Labs presented the following posters at the recent Society of Toxicology conference in Phoenix, AZ. Click on the title to download a copy.